We suggest thatfurther progress towards NHE1 inhibition as a treatment for cardiovasculardisease is warranted through the development of novel compounds to inhibit NHE1that are structurally different than those previously used in compromisedclinical trials. Here, SLC9A1 is linked to cardiovascular disorder.